These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1773911)

  • 41. Flavonoid rich fraction of Punica granatum improves early diabetic nephropathy by ameliorating proteinuria and disturbed glucose homeostasis in experimental animals.
    Ankita P; Deepti B; Nilam M
    Pharm Biol; 2015 Jan; 53(1):61-71. PubMed ID: 25289530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats.
    Gandhi S; Srinivasan B; Akarte AS
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):3-13. PubMed ID: 22791702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Double-blind study of the effect of various intra-arterial/intravenous prostaglandin E1 doses on hemodynamics and prostaglandin E1 metabolites].
    Rudofsky G; Peskar BA
    Vasa Suppl; 1991; 33():345. PubMed ID: 1788751
    [No Abstract]   [Full Text] [Related]  

  • 44. Green tea polyphenols and dietary fibre protect against kidney damage in rats with diabetic nephropathy.
    Yokozawa T; Nakagawa T; Oya T; Okubo T; Juneja LR
    J Pharm Pharmacol; 2005 Jun; 57(6):773-80. PubMed ID: 15969933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective effects of oxymatrine on experimental diabetic nephropathy.
    Guo C; Han F; Zhang C; Xiao W; Yang Z
    Planta Med; 2014 Mar; 80(4):269-76. PubMed ID: 24535719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of urokinase on preservation of renal function in patients with diabetic nephropathy.
    Sakai H; Watanabe S; Inoue I; Tanaka K; Yagame M; Machimura H; Kaneshige H; Nomoto Y
    J Diabet Complications; 1991; 5(2-3):95-7. PubMed ID: 1770066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current issues in treating the hypertensive patient with diabetes: focus on diabetic nephropathy.
    Cziraky MJ; Mehra IV; Wilson MD; Bakris GL
    Ann Pharmacother; 1996; 30(7-8):791-801. PubMed ID: 8826564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
    Lewis EJ; Hunsicker LG; Bain RP; Rohde RD
    N Engl J Med; 1993 Nov; 329(20):1456-62. PubMed ID: 8413456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial effects of eicosapentaenoic acid for diabetic patients with arteriosclerosis obliterans.
    Okuda Y; Mizutami M; Tanaka K; Isaka M; Yamashita K
    Diabetes Res Clin Pract; 1992 Nov; 18(2):139-40. PubMed ID: 1478154
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapeutic effect of alprostadil in diabetic nephropathy: possible roles of angiopoietin-2 and IL-18.
    Luo C; Li T; Zhang C; Chen Q; Li Z; Liu J; Wang Y
    Cell Physiol Biochem; 2014; 34(3):916-28. PubMed ID: 25200363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A rare case of arteriosclerosis obliterans without prominent risk factors complicated by idiopathic thrombocytopenic purpura. A case report.
    Yamagishi S; Ohta M; Segawa C; Abe T; Sawada T
    Angiology; 1996 Apr; 47(4):413-7. PubMed ID: 8619516
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Continuous intra-arterial perfusion of prostaglandin E1 in inoperable stage-IV arteriopathies].
    Gruss JD; Bartels D; Haidar A; Vargas H; Simmenroth H
    J Mal Vasc; 1983; 8(2):133-7. PubMed ID: 6683740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal function changes in diabetic nephropathy induced by bezafibrate.
    Bruce R; Daniels A; Cundy T
    Nephron; 1996; 73(3):490. PubMed ID: 8832617
    [No Abstract]   [Full Text] [Related]  

  • 54. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes.
    Beach KW; Strandness DE
    Diabetes; 1980 Nov; 29(11):882-8. PubMed ID: 7429028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostaglandin E1 for renal function preservation in transplant patients: no further trials required.
    Candela-Toha AM; Martiínez-Perez A; Liano F
    Transplantation; 1999 Jul; 68(1):166-7. PubMed ID: 10428290
    [No Abstract]   [Full Text] [Related]  

  • 56. [Hemodynamic changes of the portal venous system induced by continuous infusion of prostaglandin E1 into the superior mesenteric artery].
    Nishida O; Moriyasu F; Nakamura T; Ban N; Miura K; Sakai M; Uchino H; Miyake T
    Nihon Shokakibyo Gakkai Zasshi; 1985 Oct; 82(10):2594-600. PubMed ID: 4087469
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy.
    Okada S; Ogino Y; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z; Hiraki Y
    J Int Med Res; 1991; 19(6):497-500. PubMed ID: 1773911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
    Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
    J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does a dose of 40 micrograms/day prostaglandin E1 reduce creatinine clearance in a patient with diabetic nephropathy of the nephrotic type?
    Okada S; Hamada H; Ichiki K; Tanokuchi S; Ishii K; Ota Z; Hiraki Y
    J Int Med Res; 1992 Apr; 20(2):190-6. PubMed ID: 1521675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study.
    Shima A; Miyamoto M; Kubota Y; Takagi G; Shimizu W
    J Nippon Med Sch; 2015; 82(2):84-91. PubMed ID: 25959199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.